ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.6600
-0.1200 (-2.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.7800
Open4.7500
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range4.6200 - 4.7699
52 Week Range2.0800 - 6.9600
Volume306,238
Avg. Volume1,144,151
Market Cap216.005M
Beta (3Y Monthly)3.48
PE Ratio (TTM)N/A
EPS (TTM)-1.4550
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.79
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection.  The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin.

  • ADMA Biologics: Wall Street Projects Robust Revenue Growth
    Market Realist22 days ago

    ADMA Biologics: Wall Street Projects Robust Revenue Growth

    Why ADMA Biologics Stock Soared Yesterday(Continued from Prior Part)Revenue growth estimates ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest

  • Why ADMA Biologics Stock Soared Yesterday
    Market Realist23 days ago

    Why ADMA Biologics Stock Soared Yesterday

    Why ADMA Biologics Stock Soared YesterdayShare price movements Yesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price, 143.27% higher than its 52-week low of $2.08, and 27.30% lower than its

  • Benzinga23 days ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • GlobeNewswire23 days ago

    ADMA Receives Department of Health and Human Services U.S. License

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Department of Health and Human Services U.S. license No. 2019 to the Company in connection with the approval of ASCENIV™ Immune Globulin Intravenous, Human – slra 10% Liquid.

  • Benzinga24 days ago

    ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

    ADMA announced Monday after the market close that the FDA approved its Asceniv, a novel, patented, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease, or PIDD, in adults and adolescents ages 12-17. PIDD is a collective name for more than 300 diseases that occur due to defects in the body's immune system, invariably manifesting as acute or recurrent infections. Asceniv is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends the source plasma and plasma from donors testing using its proprietary microneutralization assay.

  • MarketWatch24 days ago

    ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

    Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday, after the biopharmaceutical company said its ASCENIV treatment of primary humoral immunodeficiency disease (PIDD) was approved by the Food and Drug Administration. Trading volume jumped to 3.6 million shares, compared with the full-day average of about 577,000 shares, and enough to make the stock the most actively traded before the open. ADMA said late Monday that expect to have ASCENIV available for commercial launch during the second half of 2019. "With the receipt of ASCENIV's™ FDA approval, ADMA, at its sole option, can elect to access up to an additional $27.5M of available funding from Perceptive Advisors under ADMA's existing credit facility," said Chief Executive Adam Grossman. The stock has soared 77.3% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 16.1% and the S&P 500 has gained 14.4%.

  • Benzinga24 days ago

    The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

  • GlobeNewswire24 days ago

    FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

    Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in Adults and Adolescents (12 to 17 Years of Age)FDA Approval Triggers Funding up.

  • Associated Presslast month

    Adma Biologics: 4Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    ADMA Biologics Reports Full Year 2018 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire2 months ago

    ADMA Biologics to Present at Upcoming Investor Conferences

    Raymond James 40th Annual Institutional Investors ConferenceOppenheimer’s 29th Annual Healthcare Conference RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2019 -- ADMA Biologics,.

  • ACCESSWIRE2 months ago

    Watch These Tech Stocks Set The Pace On Tuesday 2/12/19

    ParcelPal Technology Inc (PTNYF) (PKG), ADMA Biologics Inc (ADMA), BEST Inc (BSTI), and Semiconductor Manufacturing International Corporation (SMI) represent four companies determined to innovate towards the advancement of the tech sector. Specifically, as it relates to ParcelPal, the Company saw a need and figured out a way to fill it. The Company created an on-demand marketplace where consumers can shop for anything from food to clothing.

  • GlobeNewswire2 months ago

    ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 12, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire4 months ago

    ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the Company has submitted responses to the U.S. Food and Drug Administration (“FDA”) Complete Response Letter (“CRL”) received on December 19, 2018 for BIVIGAM®’s (Intravenous Immune Globulin [Human], 10%) (“IVIG”) Prior Approval Supplement (“PAS”).

  • Have Insiders Been Buying ADMA Biologics, Inc. (NASDAQ:ADMA) Shares This Year?
    Simply Wall St.4 months ago

    Have Insiders Been Buying ADMA Biologics, Inc. (NASDAQ:ADMA) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • Here is What Hedge Funds Think About ADMA Biologics Inc (ADMA)
    Insider Monkey4 months ago

    Here is What Hedge Funds Think About ADMA Biologics Inc (ADMA)

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

  • Here's Why ADMA Biologics Is Getting Hammered Today
    Motley Fool4 months ago

    Here's Why ADMA Biologics Is Getting Hammered Today

    The company's attempt to relaunch Bivigam hit a wall -- again.

  • GlobeNewswire4 months ago

    ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, will host a conference call today to discuss the FDA’s Complete Response Letter (“CRL”), received on Wednesday, December 19th, in response to the Company’s drug substance Prior Approval Supplement (“PAS”) submission and previously approved drug product PAS submission.

  • Reuters4 months ago

    FDA declines to approve re-launch of ADMA Biologics' Bivigam

    The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said. The FDA decision comes more than two years after the drug's previous owner suspended its production. Bivigam is a treatment given through the veins for patients with primary humoral immunodeficiency, a condition that compromises the body's ability to fight infections.

  • GlobeNewswire4 months ago

    ADMA Biologics Provides Regulatory Update on BIVIGAM® PAS Submissions

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) for the drug substance Prior Approval Supplement (“PAS”) submission and previously approved the drug product PAS submission. The FDA approved ADMA’s drug product PAS submission which was comprised of fill, finish and final release information of the drug product.

  • GlobeNewswire4 months ago

    ADMA Biologics Provides Regulatory Update for BIVIGAM®

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), announces that as of the time of this press release the Company has not received any formal written communication from the U.S. Food and Drug Administration regarding BIVIGAM’s Prior Approval Supplement under the Prescription Drug User Fee Act.

  • ACCESSWIRE4 months ago

    ADMA Biologics Upcoming PDUFA Dates and Milestones

    NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ADMA Biologics, Inc. (ADMA), a biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases. ADMA improved the U.S. Food and Drug Administration compliance status for its manufacturing facility in Boca Raton, Florida, which allowed it to submit applications for approval for the relaunch of BIVIGAM® and the approval and launch of RI-002.

  • Benzinga4 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...

  • GlobeNewswire5 months ago

    Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.